Q2 EPS Forecast for CRISPR Therapeutics Lifted by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at William Blair upped their Q2 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report released on Monday, July 14th. William Blair analyst S. Corwin now expects that the company will earn ($1.48) per share for the quarter, up from their prior estimate of ($2.27). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics' FY2025 earnings at ($6.18) EPS and FY2026 earnings at ($3.29) EPS.

Several other equities analysts have also recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Piper Sandler reissued an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. Wall Street Zen raised CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. Chardan Capital reissued a "buy" rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, June 26th. Finally, Barclays cut their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Price Performance

Shares of CRSP traded up $2.41 during mid-day trading on Wednesday, hitting $55.14. 3,312,961 shares of the company's stock were exchanged, compared to its average volume of 1,963,396. The company has a market cap of $4.76 billion, a PE ratio of -12.20 and a beta of 1.82. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $63.68. The company has a 50-day simple moving average of $43.70 and a 200 day simple moving average of $41.57.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The company's quarterly revenue was up 71.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.43) EPS.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Ipswich Investment Management Co. Inc. increased its position in shares of CRISPR Therapeutics by 1.7% in the second quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company's stock worth $1,214,000 after purchasing an additional 425 shares during the period. Perigon Wealth Management LLC increased its position in shares of CRISPR Therapeutics by 9.2% in the second quarter. Perigon Wealth Management LLC now owns 18,312 shares of the company's stock worth $891,000 after purchasing an additional 1,538 shares during the period. AdvisorNet Financial Inc increased its position in shares of CRISPR Therapeutics by 20.9% in the second quarter. AdvisorNet Financial Inc now owns 6,133 shares of the company's stock worth $298,000 after purchasing an additional 1,060 shares during the period. Bouvel Investment Partners LLC increased its position in shares of CRISPR Therapeutics by 43.6% in the second quarter. Bouvel Investment Partners LLC now owns 31,161 shares of the company's stock worth $1,516,000 after purchasing an additional 9,458 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of CRISPR Therapeutics by 43.8% in the second quarter. Farther Finance Advisors LLC now owns 8,093 shares of the company's stock worth $394,000 after purchasing an additional 2,467 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider owned 6,068 shares of the company's stock, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.